Wen Wang, IASO CEO

Chi­nese CAR-T play­er books a megaround to dri­ve bustling cell ther­a­py port­fo­lio through the clin­ic

Chi­na has quick­ly emerged as a ma­jor dri­ver of on­col­o­gy R&D in re­cent years, par­tic­u­lar­ly in cell ther­a­pies where the po­ten­tial for cheap­er de­vel­op­ment has in­vestors drool­ing. Now, one play­er, with a hand­ful of ear­ly da­ta, is swim­ming in a new round of in­vestor cash.

IA­SO Bio has closed a $108 mil­lion Se­ries C that the Chi­nese and Cal­i­for­nia-based biotech said it will use to ad­vance its slate of cell ther­a­py lead pro­grams, while al­so prop­ping up a ros­ter of next-gen al­lo­gene­ic cell ther­a­pies for the fu­ture, ac­cord­ing to a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.